Australian biotech companies are heavily involved in trying to address some of the biggest unmet medical needs in the world – with the various forms of cancer being at the forefront of research and drug development. The various approaches to cancer and different sets of intellectual property – and the effects seen so far in therapeutic development programs – is one of the most fascinating sectors of the Australian life sciences industry; and although the path through clinical trials to actual use in patients is long and fraught with danger, it is also an area of great interest to investors who understand biotech.
We put 4 Aussie key cancer stocks under the microscope.
1. Kazia Therapeutics (KZA, 48 cents)
Market capitalisation: $30 million